文献速递妇科

子宫内膜癌恶性腹腔细胞学预后意义的前瞻性评估:NRG Oncology/妇科肿瘤学组GOG-210方案研究

Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol.
PubMed 文献 · Gynecol Oncol · 2025-09-03

该研究为NRG Oncology/GOG-210方案的前瞻性辅助分析,纳入2003至2011年2383例I-III期子宫内膜癌患者,比较恶性腹腔细胞学(215例)与阴性腹腔细胞学(2168例)的生存结局。恶性腹腔细胞学与复发风险增加32%、全因死亡风险增加37%相关,但校正辅助治疗后关联减弱且无统计学显著性,提示其为可能的预后因素。

要点

  • 恶性腹腔细胞学与复发风险增加32%相关(HR 1.32,95%CI 1.03-1.69,P=0.028)。
  • 恶性腹腔细胞学与全因死亡风险增加37%相关(HR 1.37,95%CI 1.06-1.78,P=0.018)。
  • 校正辅助治疗后,无复发生存和总生存的关联均无统计学显著性。

核心结论

  • 该前瞻性评估结果提示,恶性腹腔细胞学如果确实是一个预后因素,其与子宫内膜癌生存期轻度下降相关。

研究设计与样本

  • 该研究为NRG Oncology/妇科肿瘤学组GOG-210方案的前瞻性手术-病理数据辅助分析。
  • 研究纳入2003至2011年2383例I-III期子宫内膜癌患者。
  • 暴露为腹腔细胞学状态:恶性腹腔细胞学215例,阴性腹腔细胞学2168例。
  • 主要结局为无复发生存和总生存,采用倾向评分逆概率治疗加权平衡基线临床病理特征,并校正辅助治疗。

主要发现

  • 恶性腹腔细胞学组5年无复发生存率为72%,阴性腹腔细胞学组为77%,风险比1.32(95%CI 1.03-1.69,P=0.028)。
  • 恶性腹腔细胞学组5年总生存率为78%,阴性腹腔细胞学组为83%,风险比1.37(95%CI 1.06-1.78,P=0.018)。
  • 校正辅助治疗后,无复发生存的校正风险比为1.16(95%CI 0.90-1.50,P=0.24),无统计学显著性。
  • 校正辅助治疗后,总生存的校正风险比为1.22(95%CI 0.93-1.60,P=0.16),无统计学显著性。
  • 腹腔细胞学状态与辅助治疗类型对总生存可能存在交互作用(交互作用P=0.059),接受放疗作为辅助治疗时恶性腹腔细胞学与总生存下降相关,而接受化疗时则不然。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the association between malignant peritoneal cytology and survival outcomes in endometrial cancer. METHODS: This was an ancillary analysis of prospectively collected surgical-pathological data in the NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol. The study population included 2383 patients with stage I-III endometrial cancer from 2003 to 2011. Exposure was peritoneal cytology status: malignant peritoneal cytology (n = 215) or negative peritoneal cytology (n = 2168). Main outcome measures were recurrence-free survival and overall survival. Propensity score inverse probability treatment weighting was performed to balance the baseline clinico-pathological characteristics, followed by adjustment for adjuvant therapy. RESULTS: Malignant peritoneal cytology was associated with a 32% increased risk of recurrence (5-year rates, 72% versus 77%, hazard ratio 1.32, 95% confidence interval 1.03 to 1.69, P = 0.028) and 37% increased risk of all-cause mortality (78% versus 83%, hazard ratio 1.37, 95% confidence interval 1.06 to 1.78, P = 0.018) compared to negative peritoneal cytology. When controlling for adjuvant therapy, the association between malignant peritoneal cytology and survival was attenuated for both recurrence-free survival (adjusted-hazard ratio 1.16, 95% confidence interval 0.90 to 1.50, P = 0.24) and overall survival (adjusted-hazard ratio 1.22, 95% confidence interval 0.93 to 1.60, P = 0.16) without statistical significance. Peritoneal cytology status and adjuvant therapy type had a possible interaction on overall survival, and malignant peritoneal cytology was associated with decreased overall survival when radiotherapy was received as adjuvant therapy but not when chemotherapy was utilized (P-interaction = 0.059). CONCLUSION: The results of this prospective assessment suggest that malignant peritoneal cytology is a prognostic factor, if any, associated with a modest decrease in survival for endometrial cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Matsuo K, Enserro DM, Wright JD, et al. Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol. 2025. PMID: 40907199. doi:10.1016/j.ygyno.2025.08.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。